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Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR1) breast cancer may differ by
levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR1 breast cancer cases and
26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in
tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case–case and case–control comparisons
for risk factors in relation to levels of grade and quartiles (Q1–Q4) of KI67 were estimated using polytomous logistic regres-
sion models. Case–case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs.
Q151.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 151.68 (1.31, 2.16)] and current use of combined hormone ther-
apy (HT) and low grade [grade 3 vs. 150.27 (0.16, 0.44)] tumors. In case–control comparisons, nulliparity was associated
with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14)
for KI67 Q1]; obesity among women 50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88
(0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for
grade 3]. Menarcheal age and family history were similarly associated with HR1 tumors of different grade or KI67 levels.
These findings provide insights into the etiologic heterogeneity of HR1 tumors.
Introduction
Breast cancer is a heterogeneous disease at the morphological,
molecular and genomic level, deﬁning subtypes with distinct
biological and clinical behavior.1–3 Expression of hormone
receptors (HR; i.e., estrogen receptor (ER) or progesterone
receptor (PR)) distinguishes two classes of tumors thought to
derive from different cells of origin: HR1 tumors deriving
from luminal epithelial cells and HR2 from basal/
myoepithelial cells.1 In Western populations, HR1 tumors
occur more commonly (70% of tumors) and have a later age
at onset and better short-term prognosis than HR2 tumors.4,5
While epidemiological studies have shown that these two sub-
types may have distinct risk factor associations,6–9 little is
known about etiologic heterogeneity within HR1 tumors.10,11
Histologic grade is an important indicator of tumor
aggressiveness that reﬂects three features including tubule
What’s new?
Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR1) breast cancer may differ by
HR1 tumor subtypes as defined by histologic grade and proliferation level. In this report pooling risk factor data from a con-
sortium of breast cancer studies, the authors found associations between nulliparity and highly proliferative tumors; obesity
and high grade tumors; and current use of combined hormone therapy and low grade tumors. These results provide insights
into heterogeneity of HR1 tumors that may be reflective of differences in etiological pathways, and could also have implica-
tions for risk prediction of aggressive subtypes of HR1 tumors.
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formation, nuclear pleomorphism and mitotic count, which
is directly related to proliferation.12 Due to the latter feature,
it is highly correlated with KI67 (a marker of proliferation)
and both have been used to identify surrogates for two HR1
tumors identiﬁed by expression tumor proﬁling studies, i.e.
luminal A and luminal B subtypes.13–15 Epidemiological stud-
ies suggest that these two subtypes could have differential
associations with risk factors.10,16 However, although corre-
lated, histologic grade and KI67 reﬂect different biological
features of tumors that could be of etiological relevance.
Unlike grade which encompasses both differentiation and
proliferation, KI67 is expressed only during the proliferative
phases of the cell-cycle and is one of the most commonly
used markers of proliferation.17–19 Its function is not fully
understood but it is thought to mediate assembly of the peri-
chromosomal compartment in human cells.20
Accumulating epidemiological data suggest that breast
cancer risk factors may be distinctly associated with grade
and KI67.21–23 Three previous studies found associations
between high BMI and high levels of histologic grade but not
KI6721–23 whilst younger age at onset of breast cancer and
being of African-American ethnicity were reportedly associ-
ated with high levels of KI67 but not histologic grade.23
These studies were case-series with limited sample sizes
(346–668 cases), and were based on semi-quantitative visual
scores for KI67. This scoring approach is characterized by
poor inter-observer reproducibility24,25 and offers limited
opportunities for evaluating dose–response relationships.
Thus, studies with larger sample sizes and standardized quan-
titative measures of KI67 across studies are needed to evalu-
ate the relationship between breast cancer risk factors and
HR1 tumors deﬁned by their levels of proliferation and his-
tologic grade.
In this report, we pooled risk factor data from a consor-
tium of breast cancer studies to examine the relationship of
breast cancer risk factors with subtypes of HR1 tumors
deﬁned by levels of histologic grade and KI67 expression,
determined by centralized automated scoring of tissue micro-
arrays (TMAs) as previously described.26
Materials and Methods
Study population
A total of 5,905 HR1 invasive breast cancer cases and 26,281
controls were pooled from 11 epidemiological case–control
studies with TMAs and risk factor information in the Breast
Cancer Association Consortium (BCAC). Study populations
were from Europe, Australia and North America. Details of
the contributing studies including designs, country of loca-
tion, method of recruitment, age range, sources and eligibility
of cases and controls are provided in Supporting Information
Table S1. In brief, this analysis comprised 11 case–control
studies (one of them (UKBGS) nested within a prospective
cohort study). Six studies (CNIO, MCBCS, ORIGO, RBCS,
SEARCH and kConFab) were of hospital-based or mixed
study designs (considered “non-population-based” studies),
whilst ﬁve studies (ESTHER, KBCP, MARIE, PBCS and
UKBGS) were population-based. All participants in each of
the study groups provided written informed consent and all
studies gained approval from local ethics committees.
Risk factors
Data on risk factors were derived from questionnaires that
were administered to participants at recruitment in each of
the participating BCAC studies. Harmonization, central que-
rying and quality checks on these data were performed by
investigators at the German Cancer Research Institute, Hei-
delberg. The current analysis included risk factors for which
there is evidence in the literature to suggest a heterogeneous
relationship with clinicopathological characteristics and for
which we had data. In this regard, ﬁve risk factors were iden-
tiﬁed – age at menarche, parity, body mass index (BMI), use
of combined hormone therapy (HT) and family history of
breast cancer. Supporting Information Table S2 shows the
number of cases and controls from each study with risk fac-
tor information.
Pathological characteristics
Data on hormone receptor status were obtained from clinical
records. Levels of histologic grade were assigned by local
study pathologists in the respective study groups. Tumors
were graded as 1 (low grade or well-differentiated), 2 (inter-
mediate grade or moderately differentiated) and 3 (high
grade or poorly differentiated). The extent of proliferation in
breast cancer tissues was determined using measures of KI67.
Scores were centrally generated at the Institute of Cancer
Research (ICR) in London by using a digital image analysis
protocol that was developed for the quantiﬁcation of KI67 in
breast cancer TMAs as previously described.26 In brief, a total
of 166 TMAs were collected for evaluation from the partici-
pating BCAC studies. These were stained using a standard
protocol of (Dako, Cheshire UK) MIB-1 antibody diluted 1/
50 and visualized using the Dako REAL kit (K5001). Auto-
mated scoring was performed using the Ariol machine (Leica
Biosystems, Newcastle UK), which has functionality that
allows for the discrimination of malignant and non-
malignant nuclei using shape and size characteristics as well
as the automatic detection of KI67 positive and negative
malignant nuclei using color deconvolution. The algorithm
was used to generate quantitative (0–100% positive cells)
KI67 scores. As previously reported,26 Ariol scores showed
good agreement with standardized pathologist’s scores. Subse-
quently, automated KI67 scores were merged with other risk
factor and pathological characteristics. The majority of the
5,905 cases had complete data on KI67 (83%) or grade (76%)
and at least one risk factor (see Supporting Information
Table S3 for details). All pathology data were harmonized
and quality checked by investigators at the Netherlands Can-
cer Institute, Amsterdam.
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Statistical analysis
Participant ages at diagnosis/ages at interview were catego-
rized into ﬁve classes (<40, 40–49, 50–59, 60–69 and 70).
Age at menarche was categorized into four classes (12, 13,
14, 15). Parity was deﬁned as nulliparous or parous for
case–case and case–control comparisons. For BMI, three
well-deﬁned categories were used (normal <25 kg/m2; over-
weight 25–30 kg/m2 and obese >30 kg/m2) and the case–
control analysis was conducted for groups of women strati-
ﬁed according to age (<50 years and 50 years) as a surro-
gate for menopausal status. This was done to account for
previously reported differences in the association between
BMI and breast cancer risk by menopausal status. For the
case–case comparisons, BMI was not differentially related to
tumor grade/KI67 levels by age categories (proxy for meno-
pausal status); as a result, case–case analysis was not stratiﬁed
according to age. HT use was categorized into those who
never used HT, former users and current users. Due to very
small numbers of those who reported using estrogen only
formulations, our analysis involved only those women who
took combined estrogen and progesterone formulations.
Family history of breast cancer in a ﬁrst-degree relative was
categorized as yes (if present) or no (if absent). Frequency
tables were used to assess the distribution of the risk factors
among cases and controls stratiﬁed by study design. To test
for differences in the distribution of risk factors for cases and
controls by study design, we created a dummy variable for
design and modeled this as the outcome with the different
risk factors as predictors. Box plots and nonparametric Krus-
kal–Wallis equality of median test were used to assess the
distribution of KI67 across categories of histologic grade,
overall and by study.
We constructed a polytomous unconditional logistic regres-
sion model for each risk factor variable, and performed case–
case and case–control comparisons within the same model. For
case–case comparisons, odds ratios (OR), 95% conﬁdence
intervals and p-values for the associations between breast can-
cer risk factors [menarche (12 vs. 15 years); parity (nullipa-
rous vs. parous); BMI (25–30 kg/m2 and >30 kg/m2 vs.
<25 kg/m2, respectively); HT (former and current vs. never,
respectively); family history (yes vs. no)] and quartiles of KI67
[Q1 (base category), <25th percentile (0–1.49%); Q2, 25–50th
percentile (1.50–4.29%); Q3, >50–75th percentile (4.30–
10.40%); Q4, >75th percentile (>10.40%)] and histologic
grade [grades 1 (base category), 2, 3] were estimated. For case–
control comparisons, an interaction term between study design
(population-based vs. non-population-based) and the risk fac-
tor of interest was included to obtain estimates of association
by study design. Because of previously reported biases in case–
control ORs estimated from non-population-based studies,9
only case–control ORs from population-based studies are pre-
sented in tables. However, ORs for case–case comparisons and
corresponding tests are based on data from all cases (i.e., from
both population-based and non-population-based studies).
Meta-analyses of study-speciﬁc case–case and case–control
ORs were performed to test for between-study heterogeneity in
the OR estimates.
We examined dose–response relationships between risk fac-
tors and levels of KI67, by using the median % positive cells in
each quartile of KI67 as constraints in an ordered polytomous
logistic regression model.27 To determine if the relationships
between nulliparity, obesity and current use of combined HT
are distinct with respect to grade and KI67, we applied a 2-
stage meta-regression model.28 In the ﬁrst stage of the 2-stage
meta-regression model, we performed a polytomous logistic
regression analyses for subtypes of HR1 breast cancer deﬁned
by cross-classiﬁcation of levels (Q1–Q4) of KI67 and histologic
grade (low (grade1) and high (grades 2 and 3)). In the second
stage, we modeled the subtype-speciﬁc log odds ratios and
standard errors using KI67 and grade. This approach allowed
us to evaluate if the risk factor-subtype associations are differ-
ent across subtypes deﬁned by KI67 whilst controlling for
grade, and vice versa. Also, by including an interaction term
between KI67 and grade we were able to examine if the rela-
tionship between risk factors and subtypes deﬁned by levels of
KI67 were modiﬁed by grade or vice versa.
Analysis on each risk factor was limited to studies that
provided information on that risk factor. Missing values were
addressed by creating indicators for missing values in our
models. As sensitivity analysis, all risk factors were mutually
adjusted for in a multivariate model comprising data from
three studies with information on the ﬁve risk factors that
were evaluated. All analyses, including case–case and case–
control comparisons, were adjusted for age and study. All
statistical tests were two-sided and performed using Stata
statistical software version 13.1.
Results
Table 1 shows a description of the characteristics of the study
participants based on population-based (N5 5 studies) and
non-population-based (N5 6 studies) designs. While the dis-
tribution of most risk factors in cases was similar by study
design, most risk factors showed different distributions in
population and non-population-based studies.
Overall, the median and mean positive cells stained for
KI67 was 4.2% and 8.2%, respectively. Most tumors were of
intermediate grade (52%), followed by low grade (26%) and
high grade (22%) tumors. As expected, grade 1 tumors had
lower KI67 scores compared to grades 2 and 3 tumors
[median and mean5 3% and 6.3%; 4.3% and 8%; 7% and
11% for grades 1, 2 and 3 tumors, respectively]. A similar
pattern of association between KI67 and histologic grade was
seen across studies (Supporting Information Fig. S1).
Case–case comparisons for the associations between
breast cancer risk factors and HR1 tumors defined by
levels of histologic grade and KI67
As shown in Table 2, we observed that compared to their
normal weight counterparts, tumors occurring amongst
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overweight and obese women were more likely to be of
higher (grades 2 and 3) than lower (grade 1) grade. Speciﬁ-
cally, we observed overweight women to have 33% (95%
CI5 1.13, 1.58) and 23% (95% CI5 1.00, 1.52) increased
odds of developing grades 2 and 3 than grade 1 tumors,
respectively. Similarly, high grade tumors were more likely to
occur amongst obese than normal weight women [vs. grade
1, OR (95% CI)5 1.67 (1.13, 2.05); p-value5 0.001 for grade
2 and 1.68 (1.31, 2.16); p-value5<0.001 for grade 3 tumors].
As shown in Supporting Information Table S4, these associa-
tions were similar following stratiﬁcation by tumor size (p-
value for interaction (p_interaction)5 0.52).
Compared to women who never took HT, tumors occur-
ring amongst current users of combined HT were less likely
to be high than low grade [vs. grade 1: OR (95% CI)5 0.45
(0.32, 0.63); p-value5<0.001 for grade 2 and 0.27 (0.16,
0.44); p-value5<0.001 for grade 3 tumors]. When we tested
the associations between tumor grade, KI67 and morphology
Table 1. Characteristics of cases and controls in population and non-population based studies
Population-based Non-population-based
Characteristic Controls (no.) % Cases (no.) % Controls (no.) % Cases (no.) %
Age, years
<40 252 2.2 42 2.1 590 4.7 249 6.7
40–49 1,247 10.9 293 14.4 2,135 17.0 905 24.3
50–59 3,999 34.9 682 33.6 4,696 37.4 1,456 39.1
60–69 4,720 41.1 708 34.9 3,662 29.2 882 23.7
70 1,256 10.9 303 14.9 1,464 11.7 233 6.3
Age at menarche, years
12 2,140 26.2 522 27.8 3,491 40.5 1,123 42.9
13 1,838 22.5 431 22.9 2,263 26.3 640 24.4
14 2,034 24.9 498 26.5 1,617 18.8 471 18.0
15 2,168 26.5 427 22.7 1,245 14.4 385 14.7
Parity
None 1,221 13.5 310 15.6 1,437 16.4 396 14.3
1–2 5,941 65.6 1,331 66.9 4,495 51.3 1,484 53.5
3–4 1,726 19.0 312 15.7 2,460 28.1 798 28.8
5 175 1.9 37 1.9 363 4.1 94 3.4
BMI, kg/m2
Among women <50 years
<25 542 44.4 194 51.1 672 49.7 461 52.3
25–30 431 35.3 144 37.9 387 28.6 273 31.0
>30 249 20.4 42 11.1 292 21.6 147 16.7
Among women50 years
<25 2,775 35.6 472 29.5 1,998 34.5 646 37.4
25–30 3,028 38.9 641 40.1 2,366 40.9 679 39.3
>30 2,005 25.7 486 30.4 1,419 24.5 401 23.2
Combined HT Use
Never 4,836 70.7 1,000 73.4 1,070 74.9 196 75.1
Former 849 12.4 117 8.6 238 16.7 29 11.1
Current 1,154 16.9 245 18.0 120 8.4 36 13.8
Family history
No 8,023 90.2 1,707 87.4 7,778 88.6 1,997 76.9
Yes 874 9.8 247 12.6 1,004 11.4 599 23.1
The study population comprised 11 studies participating in the Breast Cancer Association Consortium (see Supporting Information Table S1 for
details of the individual studies) with population (ESTHER, KBCP, MARIE, PBCS, UKBGS) and non-population (CNIO, kConFab, MCBCS, ORIGO, RBCS,
SEARCH) based designs. In a model with study design as the outcome: for controls, the distribution of all the risk factors differed by design (p-value
<0.05); for cases, only menarche and family history were different by design.
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(ductal vs. lobular) in relation to HT use, all three tumor fea-
tures were associated with HT use in univariate models at p-
value <0.05. However, following mutual adjustment for all
three features in a multivariable model, only histologic grade
remained associated with HT use (OR (95% CI)5 0.45 (0.27,
0.76); p-value5 0.003 for grades 2 vs. 1 and 0.25 (0.11, 0.57);
p-value5 0.001 for grades 3 vs. 1). Furthermore, as shown in
Supporting Information Table S4, HT use remained associ-
ated with low grade tumors regardless of tumor size (p_inter-
action5 0.78). Age at menarche, nulliparity and family history
of breast cancer in a ﬁrst-degree relative were not differen-
tially related to HR1 tumors deﬁned by levels of histologic
grade.
As shown in Table 3, compared to tumors occurring
among parous women, those occurring among nulliparous
women were more likely to have higher KI67 expression and
a statistically signiﬁcant gradient was observed in this rela-
tionship [OR (95% CI) vs. KI67 Q15 1.14 (1.06, 1.23) for
KI67 Q2; 1.22 (1.09, 1.37) for KI67 Q3 and 1.50 (1.20, 1.88)
for KI67 Q4; p-value for trend 0.001]. There was weaker or
no evidence for associations with KI67 levels for age at
menarche, BMI, HT and family history of breast cancer in a
ﬁrst-degree relative.
Case–control comparisons for the associations between
nulliparity, BMI, HT use and HR1 tumors defined by levels
of KI67 and histologic grade
Case–control comparisons in population-based studies
showed an elevated risk of HR1 tumors with high levels of
tumor proliferation among nulliparous women (Fig. 1 and in
Supporting Information Table S5; p-value for between-study
heterogeneity5 0.78). Furthermore, as shown in Figure 1 and
in Supporting Information Table S6, obesity amongst women
older than 50 years of age was associated with elevated risks
of high but not low grade tumors (p-value for between-study
heterogeneity5 0.76). Among women younger than 50 years
of age (Supporting Information Table S7), we observed obe-
sity to be associated with reduced risk of breast cancer across
all levels of histologic grade, this association was however
weaker for grades 2 and 3 than grade 1 tumors (p-value for
between-study heterogeneity5 0.72). Current use of com-
bined HT was associated with an elevated risk of low but not
Table 2. Case–case odds ratios and 95% CI for the associations between breast cancer risk factors and subtypes of HR1 tumors defined by
levels of histologic grade
Histologic grade*
Grade 1
(comparison group)
Grade 2 Grade 3
Risk factor N N OR (95% CI) p-Value N OR (95% CI) p-Value
Menarche
15 years 183 417 1.00 (referent) 157 1.00 (referent)
14 years 218 497 1.01 (0.80, 1.28) 0.93 186 0.99 (0.74, 1.33) 0.97
13 years 266 529 0.96 (0.76, 1.20) 0.71 192 0.89 (0.67, 1.18) 0.42
12 years 363 836 1.09 (0.87, 1.35) 0.46 299 0.96 (0.73, 1.26) 0.77
Parity
Parous 902 2,089 1.00 (referent) 745 1.00 (referent)
Nulliparous 165 322 0.86 (0.70, 1.06) 0.16 157 1.09 (0.86, 1.40) 0.46
BMI
<25 kg/m2 454 832 1.00 (referent) 332 1.00 (referent)
25–30 kg/m2 385 929 1.33 (1.13, 1.58) 0.001 326 1.23 (1.00, 1.52) 0.05
>30 kg/m2 202 596 1.67 (1.13, 2.05) <0.0001 212 1.68 (1.31, 2.16) <0.0001
Combined HT use
Never 169 545 1.00 (referent) 156 1.00 (referent)
Former 33 76 0.71 (0.45, 1.12) 0.15 17 0.47 (0.25, 0.89) 0.02
Current 84 134 0.45 (0.32, 0.63) <0.0001 29 0.27 (0.16, 0.44) <0.0001
Family history
No 844 1,918 1.00 (referent) 399 1.00 (referent)
Yes 183 399 1.03 (0.83, 1.28) 0.78 173 1.07 (0.82, 1.40) 0.61
*Histologic grade (15 low/well-differentiated; 25 intermediate/moderately differentiated; 35high/poorly differentiated). ORs and corresponding
tests are based on data from all cases i.e. both population and non-population-based. All models were adjusted for age and study and no evidence
was observed of between-study heterogeneity in study-specific OR estimates for BMI (p-value50.96) and HRT (p-value50.95).
Statistically significant p-values are indicated in bold.
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Table 3. Case–case odds ratios and 95% CI for the associations between breast cancer risk factors and subtypes of HR1 tumors defined by levels of tumor proliferation indicated by KI67
KI67*
Q1 (comparison
group) Q2 Q3 Q4
Risk factor N N OR (95% CI) P-Value N OR (95% CI) p-Value N OR (95% CI) p-Value p_trend
Menarche
15 years 206 209 1.00 (referent) 196 1.00 (referent) 201 1.00 (referent)
14 years 236 263 1.11 (0.85, 1.14) 0.45 244 1.07 (0.82, 1.41) 0.60 226 0.96 (0.73, 1.26) 0.76 0.49
13 years 302 253 0.85 (0.65, 1.10) 0.22 262 0.96 (0.74, 1.25) 0.75 254 0.94 (0.72, 1.22) 0.65 0.99
12 years 450 401 0.96 (0.75, 1.22) 0.75 384 1.01 (0.78, 1.29) 0.96 410 1.10 (0.86, 1.41) 0.44 0.30
Parity
Parous 1,119 1,011 1.00 (referent) 976 1.00 (referent) 950 1.00 (referent)
Nulliparous 158 183 1.29 (1.03, 1.64) 0.03 175 1.30 (1.03, 1.65) 0.03 190 1.54 (1.22, 1.95) <0.0001 0.001
BMI
<25 kg/m2 483 477 1.00 (referent) 411 1.00 (referent) 412 1.00 (referent)
25–30 kg/m2 504 418 0.79 (0.65, 0.95) 0.01 408 0.87 (0.72, 1.05) 0.16 419 0.86 (0.72, 1.05) 0.14 0.53
>30 kg/m2 256 250 0.86 (0.69, 1.07) 0.18 288 1.05 (0.85, 1.31) 0.64 285 0.99 (0.79, 1.24) 0.93 0.67
Combined HT use
Never 151 192 1.00 (referent) 269 1.00 (referent) 273 1.00 (referent)
Former 37 34 0.96 (0.57, 1.62) 0.88 35 0.81 (0.48, 1.36) 0.43 23 0.65 (0.37, 1.16) 0.14 0.12
Current 72 78 1.11 (0.74, 1.66) 0.60 56 0.66 (0.43, 1.00) 0.05 51 0.68 (0.44, 1.05) 0.09 0.03
Family history
No 907 923 1.00 (referent) 940 1.00 (referent) 959 1.00 (referent)
Yes 266 226 0.95 (0.76, 1.21) 0.71 182 0.89 (0.70, 1.14) 0.37 172 0.99 (0.78, 1.27) 0.98 0.97
*Quartiles (Q) of KI67 (Q1, <25 percentile (0–1.49%); Q2, 25–50th percentile (1.50–4.29%); Q3, >50–75th percentile (4.30–10.40%); Q4, >75th percentile (>10.40%)) were derived from the distri-
bution of KI67 scores. ORs and corresponding tests are based on data from all cases i.e. both population and non-population-based. All models were adjusted for age and study and no evidence
was observed of between-study heterogeneity in study-specific OR estimates for nulliparity (p-value5 0.85).
Statistically significant p-values are indicated in bold.
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high grade tumors (Fig. 1 and in Supporting Information
Table S8; p-value for between-study heterogeneity5 0.15). In
multivariate analyses with mutual adjustment for the ﬁve risk
factors that were evaluated in addition to age and study
group, nulliparity remained signiﬁcantly associated with high
but not low KI67 expressing tumors [OR (95% CI)5 1.33
(1.02, 1.74); p-value5 0.03 for KI67 Q4 and 0.85 (0.57, 1.25);
p-value5 0.40 for KI67 Q1]. Obesity among women 50
Figure 1. Case–control odds ratios (OR) and 95% confidence intervals (CI) for the associations between parity, BMI, use of combined HT
and risk of HR1 tumors defined by levels of histologic grade and tumor proliferation, indicated by KI67. Levels of KI67 defined by quartiles
of expression (Q1, <25th percentile (0–1.49%); Q2, 25–50th percentile (1.50–4.29%); Q3, 50–75th percentile (4.30–10.40%); Q4, >75th
percentile (>10.40%)). Histologic grade defined as: 15well-differentiated; 25moderately differentiated and 35poorly differentiated. All
models were adjusted for age and study. No evidence was observed of between-study heterogeneity in study-specific OR estimates (p-val-
ue>0.05). For more details see Supporting Information Tables S5, S6 and S8.
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years of age remained signiﬁcantly associated with high but
not low grade tumors [OR (95% CI)5 1.50 (1.04, 2.18); p-
value5 0.03 for grade 3 and 0.82 (0.58, 1.15); p-value5 0.26
for grade 1]. Current use of combined HT remained signiﬁ-
cantly associated with low but not high grade tumors [3.04
(2.19, 4.21); p-value <0.001 for grade 1 and 0.89 (0.58, 1.38);
p-value5 0.61 for grade 3].
When we examined the associations between nulliparity,
obesity, HT use and subtypes of HR1 tumors deﬁned by
cross-classiﬁcation of levels of KI67 and histologic grade
(Table 4), we observed nulliparity to be more strongly associ-
ated with tumors expressing higher levels of KI67 and this
association remained signiﬁcant after accounting for grade
(p-value5 0.04) and was not modiﬁed by grade (p_inter-
action5 0.37). Grade was determined to be the primary tumor
characteristic associated with obesity (p-value5 0.03) and
this was regardless of KI67 levels (p_interaction5 0.59). Fur-
thermore, HT use was more strongly associated with subtypes
characterized by being low grade. We observed grade, not
KI67, to be the primary tumor characteristic associated with
HT use (p-value5 0.008) and there was no evidence to sug-
gest that this association is dependent on levels of KI67 in
the tumor (p_interaction5 0.48).
Discussion
Findings from analyses including almost 6,000 cases with
HR1 tumors provide evidence for heterogeneity within these
tumors by histologic grade and level of proliferation. Nulli-
parity was primarily associated with risk of HR1 tumors
with high levels of proliferation deﬁned by KI67; whilst BMI
and HT were associated with risk of high and low grade
HR1 tumors, respectively.
Epidemiological studies have shown that nulliparity is more
consistently associated with increased risk for HR1 than HR2
breast cancer.7,9,29,30 Our analyses indicate that nulliparity is
primarily associated with an elevated risk of HR1 tumors with
high levels of proliferation, which is consistent with ﬁndings
from a previous prospective study.31 These ﬁndings could
reﬂect parity-related mechanisms inﬂuencing the proliferative
potential of mammary epithelial cells via the induction of ter-
minal differentiation.32 This is in keeping with animal studies
that show pregnancy-mediated persistent increase in the differ-
entiated state of the mammary gland, in addition to reduction
in epithelial cell proliferation mediated, at least in part, by the
downregulation of growth factors and the upregulation of
growth-inhibitory molecules.33
Postmenopausal obesity is associated with an elevated risk
of breast cancer that is more consistent for the HR1 sub-
type.34 Consistent with our ﬁndings, previous studies have
reported a higher frequency of high grade21–23 and large35
tumors amongst obese women; however, it is unclear whether
these reported observations are driven by grade, tumor size
or proliferation since these features are correlated but seldom
studied simultaneously. Our analyses indicate that grade is
the primary tumor characteristics related to obesity. Several
biological pathways involving estrogen metabolism,36,37 insu-
lin resistance, inﬂammation and altered adipokine and cyto-
kine production, have been proposed to mediate the obesity-
cancer link.38 It is plausible that obesity-induced systemic
and/or intra-tumoral inﬂammation may contribute to the
emergence, via cancer immunoediting39 and/or noncellular
Table 4. Odds ratios (OR) and 95% CI for the associations between parity, obesity, HT and subtypes of HR1 tumors defined by cross-
classification of levels (Q1–Q4) of KI67 and histologic grade
Parity Obesity Combined HT
Nulliparous vs. parous Obese vs. normal Current vs. never
Subtype N KI67 Grade OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
Controls 11,475 1.00 (referent) 1.00 (referent) 1.00 (referent)
1 102 Q1 Low 0.74 (0.38, 1.44) 0.38 0.98 (0.53, 1.80) 0.94 3.88 (2.14, 7.04) <0.0001
2 155 Q2 Low 1.56 (1.03, 2.42) 0.03 0.75 (0.46, 1.21) 0.24 2.91 (1.72, 4.92) <0.0001
3 123 Q3 Low 1.68 (1.05, 2.69) 0.03 0.88 (0.52, 1.49) 0.63 2.08 (1.14, 3.80) 0.02
4 79 Q4 Low 2.16 (1.24, 3.74) 0.006 0.93 (0.49, 1.77) 0.83 2.77 (1.41, 5.44) 0.003
5 300 Q1 High 0.84 (0.57, 1.14) 0.35 1.14 (0.83, 1.58) 0.41 1.13 (0.74, 1.73) 0.56
6 370 Q2 High 1.19 (0.88, 1.62) 0.25 1.30 (0.97, 1.76) 0.08 1.69 (1.19, 2.42) 0.004
7 451 Q3 High 1.28 (0.97, 1.69) 0.08 1.80 (1.35, 2.39) <0.0001 1.20 (0.84, 1.72) 0.29
8 553 Q4 High 1.37 (1.07, 1.76) 0.01 1.48 (1.14, 1.93) 0.003 1.26 (0.91, 1.77) 0.16
KI671 1.19 (1.01, 1.39) 0.04 1.09 (0.93, 1.27) 0.22 0.95 (0.79, 1.15) 0.51
Grade2 0.75 (0.51, 1.11) 0.12 1.63 (1.08, 2.46) 0.03 0.47 (0.30, 0.74) 0.008
Subtypes were defined by cross-classification of levels (Q1–Q4) of KI67 and histologic grade (low5 grade 1 and high5 grades 2 and 3).
p_interaction5 0.37 for parity, 0.59 for obesity and 0.49 for HT.
1Association between KI67 (high vs. low) and parity, obesity and HT after accounting for histologic grade.
2Association between grade (high vs. low) and parity, obesity and HT after accounting for KI67.
Statistically significant p-values are indicated in bold.
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mechanisms,40 of aggressive forms of breast tumors. Further
studies will be required to unravel the mechanisms underpin-
ning the relationship between BMI and breast cancer histo-
pathological characteristics.
Use of combined HT has been shown in epidemiological
studies to be consistently associated with tumors with favor-
able biological proﬁle including HR1, lobular or tubular
morphology, small and low grade tumors.35,41–44 In line with
these reports, we found an association between HT and
HR1 low grade tumors, that is independent of KI67. The
current analysis includes data from a previously published
study (PBCS) where we reported an association with low
grade but did not measure KI67.35 HT use is known to be
more strongly associated with the invasive lobular cancers,
typically low grade and low proliferating,45,46 than with no-
special-type (NST) invasive ductal carcinomas, which repre-
sent 50–70% of all invasive cancers. However, our analyses
indicated that HT use predisposes similarly to low grade
tumors, independently of morphology. More active screening
among HT users may lead to detection of tumors with more
favorable features including being low grade. Due to lack of
information on screening history and mode of detection, we
were unable to directly examine the impact of screening on
our ﬁndings. We did this indirectly, by using tumor size as
proxy for mode of detection and observed HT to be associ-
ated with low grade tumors regardless of tumor size (p-value
for heterogeneity5 0.78). Thus, our ﬁndings could reﬂect a
biological role for HT in inﬂuencing tumor behavior; how-
ever, further studies directly accounting for screening history
and mode of detection will be needed to clarify relationships.
Postmenopausal obesity has been shown to increase the risk
of breast cancer only among women who do not take
HT.47,48 We stratiﬁed our case–case analyses by HT use and
our results remained essentially the same even though num-
bers of cases were small.
An important strength of this analysis is that we centrally
generated continuous measures of tumor proliferation using
automated digital-pathology algorithms to score KI67. As we
previously showed, this provides standardized, highly repro-
ducible measures of KI67 with good agreements with pathol-
ogists’ quantitative and semi-quantitative scores.26 This
allowed us to evaluate dose–response relationships using
quartiles, rather than arbitrary dichotomous categories of
tumor proliferation. In addition, data on other pathology
markers enabled us to evaluate breast cancer risk factors in
relation to both KI67 and grade in the context of tumor size
and morphology.
KI67 scores were obtained from TMAs that are generally
lower than those obtained on whole sections.49 In addition,
we used an automated system to generate KI67 scores that
are usually lower than visual scores, regardless of whether
measurement was made on TMAs or whole sections.26,50
Thus, our scores for proliferation were lower than what is
typically obtained for whole sections or following visual scor-
ing on TMAs. Nonetheless, measurements from different
sources are generally well correlated and unlikely to substan-
tially affect the ranking of cases in relation to levels of KI67
used in our analyses. Measurement error is a notable limita-
tion for KI67 but automated methods are highly reproducible
and show adequate accuracy in relation to standardized path-
ologists’ scores.26,51 Furthermore, measurement error is
unlikely to be differential with respect to risk factors, and
therefore it would tend to under-rather than over-estimate
odds ratios. Histologic grade tends to have low reproducibil-
ity within and between pathologists,52 however, this error is
also likely to be non-differential with respect to risk factors.
Moreover, the consistency of our results with those of others
who have assessed breast cancer risk factors in relation to
KI67 and grade together,21–23,31 suggest that measurement
error is unlikely to explain our ﬁndings.
Our analyses comprised multiple studies with different
study designs, including population and non-population-
based studies: non-population-based studies are particularly
prone to biases in case–control measures of association since
the distribution of exposures amongst controls often does not
reﬂect that in the source population for the cases. To address
this, we limited case–control comparisons to population-
based studies only. Tests of heterogeneity of associations by
study revealed no evidence of heterogeneity of effect esti-
mates for both case–control and case–case comparisons.
Missing data on risk factors were another limitation in our
study, particularly for case–control comparisons. To address
this, we limited the analysis for each risk factor to studies
with data on that risk factor in both cases and controls and
used the conventional approach of creating indicators for
missing values on each risk factor in our regression models.
As sensitivity analyses, we performed multivariate analyses
with mutual adjustment for all ﬁve risk factors in three stud-
ies with complete information on all covariates and our
results remained essentially the same.
In conclusion, our ﬁndings indicate that the associations
between parity, BMI, use of combined HT and risk of HR1
tumors are heterogeneous depending on the levels of histo-
logic grade and proliferation, indicated by KI67. Although
correlated, histologic grade and KI67 appear to be distinctly
related to breast cancer risk factors. These results provide
insights into heterogeneity of HR1 tumors that may be
reﬂective of differences in etiological pathways; however,
other factors not evaluated in our study, such as screening,
could play a role. Given that grade and proliferation are
important prognostic factors in HR1 breast cancer, these
ﬁndings could have implications for risk prediction of aggres-
sive forms of HR1 tumors. Further studies accounting for
multiple correlated tumor characteristics and screening are
needed to enable better understanding of these relationships.
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